Study says over half of the new cancer cases and two-thirds of the cancer deaths will be in low and middle income countries, ...

Researchers have found in a new clinical trial that a single dose of clesrovimab, a long-acting investigational monoclonal ...

Published on 24 September in Nature Immunology, the researchers suggest that fibroblasts show potential as universal drug targets due to their involvement in multiple diseases across a range of ...

The number of people living with HIV in Bulawayo has declined from 79 711 in 2020 to 76 608 in 2024, as new infections continue to fall in response to significant progress in prevention and treatment.

New infections drop 44 percent | The Herald (Top Stories) Raymond Jaravaza, ray.jaravaza@gmail.com THE number of people living with HIV in Bulawayo has declined from 79 711 in 2020 to 76 608 in 2024, ...

A hard-to-treat superbug is spreading faster than many labs can track. What the data show—and what hospitals must do now.

The bispecific antibody linvoseltamab introduces a patient-centric advancement, with its response-adapted dosing regimen, a flexible approach that aims to reduce the treatment burden for patients ...

ProteCoat™ is a non-toxic antimicrobial coating technology developed by Reactive Surfaces aimed at reducing healthcare-associated infections (HAIs) in hospitals and public spaces ...